Skip to main content

Posts

OBIT: Dr. Paul Satz

From UCLA: Obituary: Paul Satz Obituary: Paul Satz, 77, psychiatry professor, founder of UCLA neuropsychology program By Mark Wheeler June 25, 2010 UCLA Paul Satz, a UCLA professor emeritus of psychiatry and biobehavioral sciences and the founder of the neuropsychology program at UCLA's Semel Institute for Neuroscience and Human Behavior and Resnick Neuropsychiatric Hospital, died June 20, in Lihue, Hawaii, after a long battle with cancer. He was 77. One of the founders of the discipline of neuropsychology, Satz was widely recognized for his groundbreaking research on brain–behavior relations. During his tenure at UCLA (1981–2002), he established the UCLA Neuropsychology Program and helped turn it into one of the world's largest and most successful training programs for clinical neuropsychologists. The author of more than 300 publications, Satz's scientific contributions to the understanding of normal and abnormal brain development had — and continue to have — a major imp...

NCDEU

NCDEU is an annual conference that presents advances in treatment and in clinical trials for a number of psychiatric conditions. It is a relatively small conference with a nicely organized agenda of workshopa, presentations, and poster sessions. The website for the conference can be found here , which includes the program.

NIH Videocast: Network Neuroscience

From the 17th of May, 2010: Network Neuroscience - Connectivity and Dynamics of the Human Brain by Dr. Olaf Sporns View the presentation "Nervous systems are complex networks of interconnected neural elements that engage in spontaneous or evoked dynamics. Recent advances in the quantitative analysis and modeling of complex networks have provided new insights into the architecture of brain, structural and functional connectivity ¬ its small-world topology, efficient information flow, low wiring cost, modularity, and hubs. This talk provides an overview of this emerging field, with an emphasis on how complex network approaches can reveal structure/function relationships in the human brain."

"The Lion's Face" - An Opera About Dementia

From The Guardian : Maps of the mind: The Lion's Face How do you write an opera about dementia? Poet Glyn Maxwell on the moving journey that produced The Lion's Face Glyn Maxwell guardian.co.uk Tuesday 25 May 2010 21.46 BST "Three years earlier, I had been asked by the composer Elena Langer to write a libretto for an opera about Alzheimer's. My first thoughts about the disease were mostly wrong. Knowing nothing about the subject, I did what poets do: I tried out some verse-forms – villanelles, pantoums, ghazals. I was falling into the trap of substituting the patterned oddities of poetry for the dire incoherences of dementia, looking for lyricism by default. "The more I learned, the better the poems became. The Institute of Psychiatry in south London's Denmark Hill opened its doors to Elena and me. We talked to scientists and researchers, saw x-rays and brain scans. We met care-givers, psychologists, music and drama therapists. We saw good care homes where we...

Alzheimer's Disease: Watch NIH Conference Live Online

From the NIH: NIH State-of-the-Science Conference: Preventing Alzheimer's Disease and Cognitive Decline - Day 1 View event: You will be able to view the event at http://videocast.nih.gov when the event is live. Air date: Monday, April 26, 2010, 8:30:00 AM Time displayed is Eastern Time, Washington DC Local [snip] Description: For many older adults, cognitive health and performance remain stable, with only a gradual and slight decline in short-term memory and reaction times. Others, however, progress into a more serious state of cognitive impairment or into various forms of dementia, including Alzheimer’s disease. In addition to investigating the causes and potential treatments for Alzheimer’s and other dementias, researchers are focused on finding ways to prevent cognitive decline. Many preventive measures for cognitive decline and for preventing Alzheimer’s have been suggested, but their value in delaying the onset and/or reducing the severity of decline or disease is unclear. B...